TickerKhojComparison · NSE · data 2026-11-02
Sanofi India Limited vs Supriya Lifescience Limited
In plain words
Size: Sanofi India Limited is about 1.1 times the market value of Supriya Lifescience Limited.
Valuation (P/E): Supriya Lifescience Limited 34.4 vs Sanofi India Limited 20.8.
Return on equity: Sanofi India Limited 40.6% vs Supriya Lifescience Limited 19.1%.
Profit growth over 3 years: Supriya Lifescience Limited 32.5% a year vs Sanofi India Limited -19.3% a year.
Debt to equity: Sanofi India Limited 0.02 vs Supriya Lifescience Limited 0.
Differences in the numbers, not a recommendation of either stock.
Side by side
| SANOFI | SUPRIYA | |
|---|---|---|
| Price | ₹3,289.3 | ₹847.8 |
| Market cap | ₹7,380 cr | ₹6,810 cr |
| P/E | 20.8 | 34.4 |
| P/B | — | — |
| ROE | 40.6% | 19.1% |
| ROCE | 54.6% | 22.3% |
| Debt / equity | 0.02 | 0 |
| Operating margin | 26.3% | 29.7% |
| Dividend yield | 3.84% | 0.12% |
| Sales growth, 3 years (yearly) | -12.8% | 21.2% |
| Profit growth, 3 years (yearly) | -19.3% | 32.5% |
| 1-year return | -31.5% | 12.5% |
| Revenue, last 12 months | ₹1,822 cr | ₹873 cr |
| Net profit, last 12 months | ₹365 cr | ₹198 cr |
| Latest quarter | Sept 2026 | Jun 2026 |
| Quarter net profit | ₹117 cr | ₹24 cr |
| Quarter profit vs a year earlier | +53.6% | -30.9% |
| Promoter holding | 60.40% | 68.30% |
| Health check | Average (6.3/10) | Strong (7.3/10) |
Common questions
Which has a higher P/E, Sanofi India Limited or Supriya Lifescience Limited?
Supriya Lifescience Limited trades at the higher P/E (34.4 against 20.8). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Sanofi India Limited (40.6% against 19.1%).
Which carries more debt?
Sanofi India Limited has the higher debt-to-equity ratio (0.02 against 0).